Research programme: glucagon-like peptide-1 modulators - Nxera Pharma
Alternative Names: GLP-1 antagonists; Glucagon-like peptide 1 antagonistsLatest Information Update: 02 Apr 2024
At a glance
- Originator Medical Research Council
- Developer Nxera Pharma
- Class Antihypoglycaemics; Peptides
- Mechanism of Action Glucagon-like peptide-1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hyperinsulinaemia; Hypoglycaemia